The acquisition by Mundipharma aims to intensifying focus on infectious diseases
In a recent announcement, Mundipharma, a leading global pharmaceutical company, has announced its acquisition of all assets and rights related to rezafungin from Cidara Therapeutics.
This solidified Mundipharma’s dedication to managing infectious diseases and specialty care therapeutic areas, especially invasisve candidiasis which over the 15 years has seen no new therapeutic developments underscoring for alternative options.
The FDA and MHRA approved rezafungin is a groundbreaking once-weekly echinocandin antifungal drug specifically designed for the treatment of invasive candidiasis in adults.
While Mundipharma will oversee global commercialization efforts, Melinta Therapeutics will retain commercialization rights for rezafungin in the United States.
Moreover, the acquisition empowers the pharmaceutical company with global ownership of rezafungin, encompassing its ongoing development and distribution.
According to Marc Princen, Mundipharma’s Chief Executive Officer, the strategic move positions the company to fully unleash the potential of rezafungin which has been granted Orphan Drug Designation in multiple regions, emphasizing its significance in addressing unmet medical needs.
“We are committed to ensuring patients affected with invasive candidiasis have access to an additional treatment option to manage this potentially life-threatening condition,” Princen said.
Currently available to patients in the UK and Germany, Mundipharma aims to expedite further marketing authorizations to extend patient access.
The acquisition underscores Mundipharma’s unwavering commitment to advancing therapeutic solutions for critical medical conditions, reaffirming its position as a frontrunner in the global healthcare landscape.
What is Invasive Candidiasis?
Invasive candidiasis a severe and potentially life-threatening infection of the bloodstream and/or deep tissues. This condition predominantly affects individuals with compromised immune systems, with mortality rates exceeding 40 per cent.
*Assets and rights acquired by Napp Pharmaceutical Group Limited, a member of the international network of Mundipharma independent associated companies.*
